Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Elucidating the effect of empagliflozin on the cardiac and renal sympathetic outflows in patients with type 2 diabetes

Trial Profile

Elucidating the effect of empagliflozin on the cardiac and renal sympathetic outflows in patients with type 2 diabetes

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 11 Dec 2018

At a glance

  • Drugs Empagliflozin (Primary)
  • Indications Cardiovascular disorders; Coronary artery disease
  • Focus Pharmacodynamics
  • Most Recent Events

    • 05 Dec 2018 Status changed from not yet recruiting to recruiting.
    • 14 Mar 2018 Planned initiation date changed from 18 Apr 2017 to 1 Apr 2018.
    • 06 Apr 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top